-
1
المؤلفون: Sandrine Mansard, Philippe Saiag, Hervé Maillard, Amine Denden, Caroline Robert, Laurent Mortier, S. Dalac-Rat, Charlée Nardin, Olivier Dereure, Thierry Lesimple, Laurent Machet, Eve-Marie Neidhardt, Florent Grange, Alexandra Szenik, Caroline Dutriaux, Christophe Bedane, Céleste Lebbé, Jean-Jacques Grob
المساهمون: HAL UVSQ, Équipe, Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Hôpital Ambroise Paré [AP-HP], Service de dermatologie, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Lille, Université de Lille, CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Léon Bérard [Lyon], Centre Eugène Marquis (CRLCC), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université Francois Rabelais [Tours], Service de Dermatologie [CHU Limoges], CHU Limoges, Service de dermatologie [CH Le Mans], Centre Hospitalier Le Mans (CH Le Mans), Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Novartis Pharma S.A.S., CHU Bordeaux [Bordeaux], Amgen, Bristol-Myers Squibb, BMS, Pfizer, Merck, Novartis, Roche, Sanofi, Meso Scale Diagnostics, MSD, Novartis Pharma, Les Laboratories Pierre Fabre, This work was supported by Novartis Pharma S.A.S. , France., Philippe Saiag has received personal fees from Amgen, Bristol-Myers Squibb, MSD, Merck-Serono, Pfizer, Roche-Genentech, Pierre Fabre, Sanofi and Novartis, he has received non-financial support from Bristol-Myers Squibb, MSD, Roche-Genentech and Novartis, and has received a funding grant from Roche-Genentech., Céléste Lebbe has received honoraria from BMS, MSD, Roche, Novartis, Amgen, Merck, Pierre Fabre, Pfizer and Incyte, has acted as a consultant or has served as a member of an advisory board for BMS, and has received travel grant support from BMS and MSD., Jean-Jacques Grob has received honoraria from BMS, MSD, Merck, Pfizer, Incyte, Novartis, Roche, Amgen and Pierre Fabre, has received travel grant support from BMS, MSD and Roche, and has acted as a consultant and advisor for BMS, MSD, Roche, Novartis, Amgen, Merck, Pierre Fabre, Pfizer and Incyte., Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)
المصدر: European Journal of Cancer
European Journal of Cancer, 2021, 154, pp.57-65. ⟨10.1016/j.ejca.2021.05.031⟩
European Journal of Cancer, Elsevier, 2021, 154, pp.57-65. ⟨10.1016/j.ejca.2021.05.031⟩مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, Oncology, Cancer Research, medicine.medical_specialty, Pyridones, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Pyrimidinones, 030204 cardiovascular system & hematology, Regression tree, 03 medical and health sciences, BRAF V600-mutation, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Trametinib, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, medicine, Humans, Prospective Studies, Stage (cooking), Prospective cohort study, education, neoplasms, Melanoma, Aged, Neoplasm Staging, education.field_of_study, Proportional hazards model, business.industry, Dabrafenib, Imidazoles, Middle Aged, medicine.disease, 3. Good health, 030220 oncology & carcinogenesis, Mutation, Disease Progression, Female, business, Brain metastasis, medicine.drug
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7270e6beefeb71081cde6deee2aa0af2Test
https://hal.science/hal-03401780Test -
2
المؤلفون: Caroline Robert, Jacob Schachter, Thierry Lesimple, C. Dutriaux, Dirk Schadendorf, Monique Tan, Axel Hauschild, Georgina V. Long, R. Dummer, Eduard Gasal, Mario Santinami, Kohinoor Dasgupta, James Larkin, Mario Mandalà, Andrew M. Haydon, John M. Kirkwood, Vanna Chiarion Sileni, Laurent Mortier, Victoria Atkinson, Marta Nyakas, Ruth Plummer
المساهمون: University of Zurich
مصطلحات موضوعية: Male, Oncology, Skin Neoplasms, medicine.medical_treatment, Medizin, Administration, Oral, 2700 General Medicine, 030204 cardiovascular system & hematology, law.invention, 0302 clinical medicine, Randomized controlled trial, law, Antineoplastic Combined Chemotherapy Protocols, Oximes, Medicine, 030212 general & internal medicine, Neoplasm Metastasis, Melanoma, Trametinib, Imidazoles, Follow up studies, 10177 Dermatology Clinic, General Medicine, Middle Aged, Female, Adjuvant, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, 610 Medicine & health, Pyrimidinones, Disease-Free Survival, 03 medical and health sciences, Adjuvants, Immunologic, Double-Blind Method, Internal medicine, Humans, Stage III melanoma, Protein Kinase Inhibitors, Survival analysis, Aged, Neoplasm Staging, business.industry, Dabrafenib, Survival Analysis, Clinical trial, Mutation, business, Follow-Up Studies
وصف الملف: 848_Dummer_R._et_al._Five-Year_Analysis_of_Adjuvant_Dabrafenib_plus_Trametinib_in_Stage_III_Melanoma_NEJM_2020.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d710d2b0f671e5dafc838391b9965d4aTest
https://www.zora.uzh.ch/id/eprint/190018Test -
3
المؤلفون: Eduard Gasal, Paul Nathan, Antoni Ribas, Neha Pakhle, Victoria Atkinson, Céleste Lebbé, Dirk Schadendorf, Mario Mandalà, Daniel Gusenleitner, Paolo A. Ascierto, Aisha Masood, Erika Richtig, Catarina D. Campbell, Reinhard Dummer, Ana Arance, Keith T. Flaherty, Hussein Abdul-Hassan Tawbi, Naoya Yamazaki, Georgina V. Long, Caroline Robert, Jan C. Brase
المساهمون: University of Zurich, Dummer, Reinhard
مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Skin Neoplasms, Medizin, Cohort Studies, 0302 clinical medicine, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Oximes, Clinical endpoint, Neoplasm Metastasis, Immune Checkpoint Inhibitors, Melanoma, Trametinib, MEK inhibitor, Imidazoles, 10177 Dermatology Clinic, General Medicine, Middle Aged, MAP Kinase Kinase Kinases, Treatment Outcome, 030220 oncology & carcinogenesis, Disease Progression, Biomarker (medicine), Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, Mutation, Missense, 610 Medicine & health, Genetics and Molecular Biology, Pyrimidinones, Antibodies, Monoclonal, Humanized, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Young Adult, 1300 General Biochemistry, Genetics and Molecular Biology, Internal medicine, medicine, Biomarkers, Tumor, Humans, Protein Kinase Inhibitors, Aged, business.industry, Dabrafenib, medicine.disease, Clinical trial, Regimen, 030104 developmental biology, General Biochemistry, business
وصف الملف: 870_Dummer_R._et_al._Combined_PD-1,_BRAF_and_MEK_inhibition_in_advanced_BRAF-mutant_melanoma_Nature_Medicine_2020.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b17ee96d80a3281cdd7448c58c9110fTest
https://www.ncbi.nlm.nih.gov/pubmed/33020648Test -
4
المؤلفون: John M. Kirkwood, James Larkin, Mario Mandalà, Richard F. Kefford, Tomas Haas, Vanna Chiarion-Sileni, Caroline Robert, Kohinoor Dasgupta, Axel Hauschild, Mario Santinami, Mark Shilkrut, Caroline Dutriaux, Eduard Gasal, Dirk Schadendorf, Georgina V. Long, Jacob Schachter, Andrew Haydon, Laurent Mortier, Ruth Plummer, Victoria Atkinson, Marta Nyakas, Thierry Lesimple, Reinhard Dummer
المساهمون: University of Zurich, Long, Georgina V
المصدر: Journal of Clinical Oncology
J Clin Oncolمصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, Internationality, Skin Neoplasms, Time Factors, Medizin, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, Clinical endpoint, 1306 Cancer Research, Stage (cooking), Melanoma, Trametinib, Hazard ratio, Age Factors, Imidazoles, 10177 Dermatology Clinic, Middle Aged, Treatment Outcome, 030220 oncology & carcinogenesis, Female, 2730 Oncology, Rapid Communication, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, 610 Medicine & health, Pyrimidinones, Placebo, Disease-Free Survival, Drug Administration Schedule, 03 medical and health sciences, Sex Factors, Adjuvants, Immunologic, Double-Blind Method, Internal medicine, Correspondence, medicine, Humans, Dose-Response Relationship, Drug, business.industry, Cancer, Dabrafenib, medicine.disease, Clinical trial, 030104 developmental biology, business, Follow-Up Studies
وصف الملف: 767_Hauschild_A._et_al._Longer_follow-up_confirms_relapse-free_survival_benefit_with_adjuvant_dabrafenib_plus_trametinib_in_patients_JCO_2018.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00393631f41ac7c8491c0de2c7f007a8Test
https://doi.org/10.5167/uzh-158265Test -
5
المؤلفون: Vanna Chiarion-Sileni, Paul Nathan, Axel Hauschild, Jeffrey J. Legos, Jacob Schachter, Mario Mandalà, Boguslawa Karaszewska, Jean-Jacques Grob, Caroline Dutriaux, Dirk Schadendorf, Daniil Stroiakovski, Michael A. Davies, Helen Gogas, John B. A. G. Haanen, Claus Garbe, Ying Zhang, Antoni Ribas, Piotr Rutkowski, Keith T. Flaherty, Georgina V. Long, Mathilde Kaper, Caroline Robert, Céleste Lebbé, Evgeny Levchenko, Bijoyesh Mookerjee, Andrzej Mackiewicz
مصطلحات موضوعية: 0301 basic medicine, Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Multivariate analysis, Combination therapy, Pyridones, Medizin, Pyrimidinones, Metastasis, 03 medical and health sciences, 0302 clinical medicine, Predictive Value of Tests, Risk Factors, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, medicine, Humans, Neoplasm Metastasis, Vemurafenib, Melanoma, Protein Kinase Inhibitors, Aged, Trametinib, L-Lactate Dehydrogenase, business.industry, MEK inhibitor, Imidazoles, Dabrafenib, Middle Aged, medicine.disease, Prognosis, Survival Analysis, Surgery, 030104 developmental biology, 030220 oncology & carcinogenesis, Female, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4136aa0fa3f1e15c66017826608bb4b0Test
https://www.ncbi.nlm.nih.gov/pubmed/28648698Test -
6
المؤلفون: Stephen R. Lane, Michael A. Davies, Jean-Jacques Grob, Philippe Legenne, Antoni Ribas, Dirk Schadendorf, Caroline Robert, Carmen Mak, Paul Nathan, Georgina V. Long, Keith T. Flaherty
مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Multivariate analysis, Pyridones, Medizin, Disease, Pyrimidinones, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, Overall survival, Medicine, Humans, Melanoma, Randomized Controlled Trials as Topic, Retrospective Studies, Trametinib, business.industry, Disease progression, Imidazoles, Dabrafenib, Retrospective cohort study, medicine.disease, Surgery, 030104 developmental biology, 030220 oncology & carcinogenesis, Mutation, Disease Progression, Female, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::044efee0647329ab4cd29a1b18d766adTest
https://www.ncbi.nlm.nih.gov/pubmed/27864013Test -
7
المؤلفون: Daniil Stroyakovskiy, Jochen Utikal, Keith T. Flaherty, Daniele Ouellet, Virginia Ferraresi, Michelle Casey, Claus Garbe, Axel Hauschild, V. Chiarion Sileni, Caroline Robert, Helen Gogas, Antoni Ribas, Michael Millward, Nadezhda Kovalenko, Jean-Jacques Grob, Jhangir G. Irani, Paul Nathan, Dirk Schadendorf, John B. A. G. Haanen, V. Probachai, Mario Mandalà, F. de Braud, Johan Hansson, Georgina V. Long, Igor Bondarenko, Kiran Patel, Ngocdiep T. Le, Anne-Marie Martin, James Larkin, Ana Arance, T. Jouary, Peter Mohr, Douglas J. DeMarini, Céleste Lebbé, Evgeny Levchenko
مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Fever, Pyridones, Medizin, Kaplan-Meier Estimate, Pyrimidinones, Gastroenterology, Disease-Free Survival, chemistry.chemical_compound, Double-Blind Method, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, Carcinoma, medicine, Clinical endpoint, Humans, Melanoma, Aged, Mitogen-Activated Protein Kinase Kinases, Cobimetinib, Trametinib, business.industry, Hazard ratio, Imidazoles, Binimetinib, Dabrafenib, General Medicine, Middle Aged, medicine.disease, Surgery, chemistry, Mutation, Female, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::266d13e0581ba3c486d28c2d159ca1daTest
http://hdl.handle.net/11391/1480877Test -
8
المؤلفون: Keith T, Flaherty, Caroline, Robert, Peter, Hersey, Paul, Nathan, Claus, Garbe, Mohammed, Milhem, Lev V, Demidov, Jessica C, Hassel, Piotr, Rutkowski, Peter, Mohr, Reinhard, Dummer, Uwe, Trefzer, James M G, Larkin, Jochen, Utikal, Brigitte, Dreno, Marta, Nyakas, Mark R, Middleton, Jürgen C, Becker, Michelle, Casey, Laurie J, Sherman, Frank S, Wu, Daniele, Ouellet, Anne-Marie, Martin, Kiran, Patel, Dirk, Schadendorf, Mary, Richardson
المصدر: The New England journal of medicine. 367(2)
مصطلحات موضوعية: Oncology, Adult, Male, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, Dacarbazine, MAP Kinase Kinase 2, Medizin, MAP Kinase Kinase 1, Antineoplastic Agents, Kaplan-Meier Estimate, Pyrimidinones, Disease-Free Survival, chemistry.chemical_compound, Young Adult, Internal medicine, medicine, Humans, Vemurafenib, Melanoma, Protein Kinase Inhibitors, Aged, Trametinib, Cobimetinib, Aged, 80 and over, business.industry, MEK inhibitor, Hazard ratio, Dabrafenib, General Medicine, Middle Aged, medicine.disease, Surgery, Intention to Treat Analysis, chemistry, Mutation, Female, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::778f247f586f7abe700c37ec7f75715aTest
http://ora.ox.ac.uk/objects/uuid:17a4cd0c-72ea-46f7-ab36-457c375b3557Test